



## EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

### MINUTES OF THE TEAMS MEETING 20<sup>th</sup> July 2022

#### PRESENT:

Dr S Ramtoola (SR)	Consultant Physician, ELHT (Chairperson)
Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL ICB
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mr J Vaughan (JV)	Senior Medicines Commissioning Pharmacist NHS EL/BwD ICB
Ms Ana Batista (AB)	Medicines Information Pharmacist ELHT
Mr U Akram (UA)	Deputy Lead Pharmacist, LS CFT
Mr C Woods (CW)	Head of Contracting and Costing, Finance
Dr F Shah (FS)	GP/Consultant MFOP & Diabetes
Mr Neil Fletcher (NF)	Director of Pharmacy ELHT
Ms L Prince (LP)	Medicines Management Technician, EL ICB
Dr S Jackson (SJ)	GP clinical Lead for Quality for Lancashire and South Cumbria ICS
Mr Mohamed Fareeth	Consultant Physician, MEC Representative

#### IN ATTENDANCE:

Mr W Price (WP)	Dermatology Specialist Pharmacist
Ms Victoria Simpson	Rheumatology and Homecare Lead Pharmacist
Mr Irfan.Hafeez	Consultant Respiratory
Ms Sally Turner	ANP Respiratory
Ms Aisha Rashid	Specialist Respiratory Pharmacist
Ms Humayrah Natha	Clinical Pharmacist
Mr Abdullah Mistry	Cardiology Lead Pharmacist
Ms Anna MacPherson	Consultant in Palliative Medicine
Dr Scot Garg	Consultant Cardiology
DR Irfan Baig	Consultant Diabetes

#### 2022/112: APOLOGIES:

Dr S Bhattacharya (SB) stepped down as a MEC representative  
Dr T Mackenzie  
Dr M Maher  
Mrs H Robinson

#### 2022/113: DECLARATION OF INTEREST

None declared - relevant to agenda items



## 2022/114: MINUTES OF JUNE TEAMS MEETING:

Accepted as a correct record

## 2022/115: MATTERS ARISING:

### 2022/089: Current and proposed RAG status for liothyronine

ELHT do not wish to use liothyronine and decision to change to RED traffic light agreed. This will be reviewed if required.

**Action:** Change to RED Traffic Light. **Resolved:** Item closed

**2022/100b: Vitamin A Palmitate 100000 units per 2 mL injections.** This was approved for use last month as an unlicensed medicine. The request and risk assessment form for unlicensed medicines has now been received.

**Resolved:** item closed

**2022/106:** Romosozumab for treating severe osteoporosis (TA791) – for treatment of severe osteoporosis. Further discussions to take place regarding criteria and management of initial cohort of patients to be referred into the service. The drug will be RED traffic light for use through Homecare services.

**ACTION:** Further meeting to be arranged to discuss outside this meeting. Item closed.

## 2022/116: New Product Request

a. **Disopyramide 100mg capsules** – requested cardiology consultant for patients with hypertrophic obstructive cardiomyopathy in cases where beta-blockers/calcium-channel blockers are ineffective to reduce ventricular outflow tract gradient. Concerns were raised that GPs may not be comfortable starting and prescribing the medication for an unlicensed use. It was agreed that the medication would be started in secondary care by the specialist and then passed to Primary Care to continue for the next 3 – 6 months

**Resolved:** Approved for use

**Traffic Light: AMBER**

b. **Stimulan Rapid Cure** – Requested for use in Diabetic foot clinic for bone and soft tissue infection to help reduce duration and use of systemic antibiotics. It was raised that this product may present safety concerns as it will be mixed on site. Outcomes and any adverse events to be collected.

**Resolved:** Only to be considered for use when pre-mixed product is unavailable and where smaller amounts are required. To be discussed at the next ASC; no need to re-discussed approval at ELMMB. Update to be given post ASC.

c. **Stimulan Rapid Cure pre-mixed with gentamicin and vancomycin** - use as above. This was agreed as the preferred product of use as it is ready-mixed and **offers** no safety issues. Consultant use only.

**Resolved:** Approved for addition to formulary as preferred option to un-mixed product.

**Traffic Light: RED**

d. **P20 face SPF 30 cream** and **P20 SPF 50 spray** – requested by dermatology for use as a sunscreen in clinic only, when patients receive daylight photodynamic therapy with a sensitizing product [Metvix] to treat mild to moderate actinic keratoses lesions.



The product will be applied in the dermatology department

**Resolved:** Approved for addition to formulary

**Traffic Light:** RED

- e. **Calcipotriol and betamethasone dipropionate cream** [Wynzora cream®] – requested by dermatology for the topical treatment of mild to moderate psoriasis vulgaris, including scalp psoriasis, in adults. This is a cream preparation which is often preferred by patients. To be prescribed generically.

**Resolved:** Approved for use

**Traffic Light:** GREEN

### 2022/117 Formulary Updates

- a. **Mometasone 50microgrms/dose nasal spray** - approved for use as first line alternative to fluticasone 50mcg/dose aqueous nasal spray. **Traffic Light: GREEN**
- b. **Pyridostigmine oral solution – Licensed preparation:** approved for use in patients with myasthenia gravis with dysphagia **Traffic Light: AMBER**
- c. **Progesterone capsules (Utrogestan)** – For progestogenic opposition of oestrogen HRT in women with an intact uterus [acknowledged from recommendations by Strategic Commissioning Committee] **Traffic Light: GREEN**
- d. **Ozurdex** (dexamethasone intravitreal implant) – For adult patients who have visual impairment due to diabetic macular oedema (DME) who are not pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy [acknowledged from recommendations by Strategic Commissioning Committee] **Traffic Light: RED**
- e. **Trimbaw NEXThaler** - For COPD – Triple therapy should be reserved for patients who have failed to achieve or maintain an adequate response to an appropriate course of dual therapy. **Traffic Light: GREEN RESTRICTED**

### 2022/118 LSCMMG Consultations – July 2022

None circulated.

### 2022/119 LSCMMG Recommendations – June 2022

- Degarelix prescriber information sheet – updated
- Hydroxychloroquine prescriber information sheet – updated
- Ivabradine prescriber information sheet – updated [AMBER 0]
- Melatonin prescriber information sheet – updated
- Clopidogrel tablets after a stroke or mini-stroke information sheet - removed
- Ciclosporin shared care guidance

**Resolved:** Items a,b,e and f were acknowledged by ELMMB. **Item c:** ELMMB have a guideline that denotes GREEN traffic Light for ivabradine in chronic stable angina. Traffic light for ELHE will remain GREEN for this indication.



**For Action: Item d** Melatonin prescriber information sheet requires further clarification from LSCMMG and evidence as to why ADHD has been classified separate from neurodevelopmental disorders.

### 2022/120 Strategic Commissioning Committee (SCC) Decisions – June 2022

- a. Progesterone capsules - Progestogenic opposition of oestrogen HRT in women with an intact uterus
- b. Ozurdex (dexamethasone intravitreal implant) - for adult patients who have visual impairment due to diabetic macular oedema (DME) who are not pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy
- c. Trimbrow® NEXThaler – COPD

**Resolved:** Acknowledged by ELMMB and added to formulary as per formulary section above

### 2022/121 Other Items

- a. GINA guidelines
- b. Greener-asthma-guideline-v1-post-april-2022

**Resolved:** Items acknowledged by ELMMB. Resources support the move to breath actuated inhalers rather than metered dose inhalers. Individual care plans will be an integral part to patient care when there are compliance issues. A strategy will be required for the hospital. A resource area to be developed on ELMMB.

### 2022/122 Other Items

Individual Funding Request (IFR) – Abstral (fentanyl sublingual tablets). This has been submitted as urgent and approved for use for 3 months. Supplies will be from the hospital pharmacy. The request will need to be submitted if use is required after 3 months.

**Resolved:** Acknowledged by ELMMB. It was noted that the request will need to be re-submitted if use is required after 3 months.

### 2022/123 Other Items

Opioid conversion chart – updated to include use of alfentanil to reduce any risk. The prn opioid doses are more measurable and clearer for patients and carers. There is also updated information on higher doses to reduce errors. The chart will be shared with primary care colleagues.

**Resolved:** Opioid conversion chart acknowledged by ELMMB and will be added to ELMMB when a review date and version number has been added.

### 2022/124 NICE Guidance - June 2022

**NG219** Gout diagnosis and management – updated 090622

**NG25** Preterm labour and birth – updated 100622



**NG220** Multiple sclerosis in adults: management – updated 220622

**NG222** Depression in adults: treatment and management – updated 290622

**NG17** Type 1 diabetes in adults: diagnosis and management – updated 290622

**NG28** Type 2 diabetes in adults: management – updated 290622

**NG18** Diabetes (type 1 and 2) in children and young people: diagnosis and management – updated 290622

**Resolved:** Items acknowledged by ELMMB

## 2022/125 NICE Recommendations – June 2022

Filgotinib for treating moderately to severely active ulcerative colitis is recommended as an option by NICE TA792. Approved in line with NICE.

ICS Commissioned. Blueteq required

**Traffic Light: RED**

Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus is not recommended as an option in NICE TA793

terminated appraisal

**Traffic Light: BLACK**

Diroximel fumarate for treating relapsing-remitting multiple sclerosis is recommended as an option by NICE TA794. Approved in line with NICE

NHS England Commissioned

**Traffic Light: RED**

Ibrutinib for treating Waldenström's macroglobulinaemia, within its marketing authorisation, in adults who have had at least 1 previous therapy is not recommended as an option as by NICE TA795.

**Traffic Light: BLACK**

Venetoclax for treating chronic lymphocytic leukaemia is recommended as an option by NICE TA796. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer is not recommended as an option in NICE TA797

terminated appraisal

**Traffic Light: BLACK**

Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation is recommended as an option by NICE TA798.

Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Faricimab for treating diabetic macular oedema is recommended as an option in line with NICE TA799. Approved in line with NICE

ICS Commissioned. Blueteq required

**Traffic Light: RED**

Faricimab for treating wet age-related macular degeneration is recommended as an option in line with NICE TA800. Approved in line with NICE

ICS Commissioned. Blueteq required

**Traffic Light: RED**

Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer is recommended as an option by NICE TA801. Approved in line with NICE.



NHS England Commissioned

**Traffic Light: RED**

Cemiplimab for treating advanced cutaneous squamous cell carcinoma is approved as an option by NICE TA802. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Teduglutide for treating short bowel syndrome is approved as an option by NICE TA804. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

**Resolved:** Items acknowledged by ELMMB

**2022/126 NICE Highly Specialised Technologies – June 2022**

None this month

**2022/127 EAMS (Early access to medicines scheme) – June 2022**

None this month

**Standing Items:**

**2022/128 For Action/Information: Lancashire & South Cumbria Medicines Management Group (LSCMMG)**

DRAFT LSCMMG minutes 09.06.2022

**Resolved:** Minutes acknowledged.

**2022/129 For Action/Information: Lancashire & South Cumbria FT Drugs and Therapeutics Committee**

Non available (next meeting 21.07.22)

**2022/130 For Action/Information: Antimicrobial Stewardship Committee (ASC)**

Non available for May meeting. Next meeting will take place in August.

**Resolved:** acknowledged by ELMMB.

**DATE OF NEXT MEETING – Wednesday 21<sup>st</sup> September 2022 12.30pm via ‘Microsoft Teams’**



**ACTION SHEET FROM  
EAST LANCASHIRE HEALTH ECONOMY  
MEDICINES MANAGEMENT BOARD**

**WEDNESDAY 20<sup>th</sup> July 2022**

<b>MINUTE NUMBER</b>	<b>DESCRIPTION</b>	<b>ACTION</b>	<b>DATE</b>
<b>2021/101b</b>	<b>ELMMB Membership</b> A review will be required to decide how ELMMB links with the ICS and ICB in the future and the policy for introduction of new drugs will required review as a result of that	LR/VG	Sep 22
<b>2022/116b</b>	<b>Stimulan Rapid Cure</b> To be discussed at the next ASC; no need to re-discussed approval at ELMMB. Update to be given post ASC.	AB	Sep 22
<b>2022/119d</b>	<b>Melatonin prescriber information sheet</b> Requires further clarification from LSCMMG and evidence as to why ADHD has been classified separate from neurodevelopmental disorders.	AB	Sept 22